Melanoma recurrent
Information
- Disease name
- Melanoma recurrent
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT02574533 | Completed | Phase 1 | Pilot Study of Vigil™ + Pembrolizumab for Advanced Melanoma | October 2015 | September 2017 |
| NCT03311542 | No longer available | Expanded Access for Pembrolizumab (MK-3475) | |||
| NCT06398418 | Not yet recruiting | Phase 1 | R-5780-01 In Combination With PD-1 Checkpoint Inhibitors (Checkpoint Protein on Immune Cells Called T Cells) in Patients With Solid Tumors | June 1, 2024 | September 30, 2026 |
| NCT04478279 | Recruiting | Phase 1/Phase 2 | A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors | July 1, 2020 | December 2025 |
| NCT05848739 | Recruiting | Phase 1 | A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors | June 5, 2023 | May 31, 2027 |